Table 2.

The effects of SESN2 on various inflammatory-related diseases.

Inflammatory disorder	Effect	References
Sepsis	Decreasing mortality rate Attenuating systemic inflammation Reducing ROS accumulation	(12, 17, 18)
Liver diseases	Protecting liver against hepatitis Inhibiting TLR-mediated pro-inflammatory response Decreasing liver injury Preventing hepatocyte death, steatohepatitis, and liver fibrosis Attenuating obesity-induced hepatic steatosis Attenuating glucose intolerance and insulin resistance	(14–18)
Ischemia–reperfusion injury	Improving post-ischemic cardiac function Decreasing heart sensitivity to ischemia insult Decreasing heart infarct areas Maintaining basal cardiac integrity Ameliorating oxidative stress insult Alleviating brain infarct areas, attenuating brain atrophy, lowering neuron apoptosis, improving the blood–brain barrier integrity, and improving long-term neurological function	(20–22, 24, 100)
Neurodegenerative diseases	Decreasing neuron apoptosis Attenuating oxidative stress Alleviating peripheral nerve injury Inhibiting inflammatory neuropathic pain	(26–28)
Cardiovascular diseases	Inhibiting chronic heart failure Attenuating smooth muscle cell apoptosis Delaying the progression of atherosclerosis	(6, 32–35, 96)
Chronic obstructive pulmonary disease	Decreasing alveolar maintenance programs Alleviating pulmonary emphysema	(36, 37, 101)
Obesity and diabetes	Maintaining glucose metabolic homeostasis Avoiding insulin resistance	(48, 102, 103)
Cancer	Inhibiting cancer cell migration Inhibiting cancer growth	(41, 43)